Floatz logo

Tisagenlecleucel

Lymphoma, B-Cell

Sun Yat-sen UniversityCell therapyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
73/ 100

Competitive context

50 Active assets in the Lymphoma, B-Cell cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mwanasha Merrill, MD
Phase 4BB
Cyclophosphamide
Swiss Cancer Institute
Phase 4BB
cd19-ucart
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4BB
(+)-VINCRISTINE
Mwanasha Merrill, MD
Phase 4BB
Inno-206
Mwanasha Merrill, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →